Low-dose antibiotic spurs gut bacteria to make a longevity-linked compound in animals, study finds

Faktatarkistettu

Researchers report that small doses of the antibiotic cephaloridine can prompt certain gut bacteria to increase production of colanic acid, a microbial polysaccharide previously tied to longer lifespan in laboratory animals. In experiments, treated roundworms lived longer and mice showed shifts in cholesterol or insulin measures associated with aging, with the team arguing the approach works by acting in the gut rather than throughout the body.

A research team led by Meng C. Wang, a senior group leader at the Howard Hughes Medical Institute’s Janelia Research Campus, has reported a strategy for coaxing gut microbes to produce higher levels of colanic acid, a bacterial product that has been linked in prior work to longer life in animal models. (sciencedaily.com)

The study, published in PLOS Biology on November 11, 2025, found that exposing certain Escherichia coli strains to a low dose of the antibiotic cephaloridine led the bacteria to overproduce colanic acids. In the roundworm Caenorhabditis elegans, animals given cephaloridine lived longer, which the researchers linked to the increase in colanic acid. (sciencedaily.com)

The team also tested the approach in mice. According to the study’s summary and the journal report, oral low-dose cephaloridine triggered gene expression in gut bacteria tied to colanic acid biosynthesis and was associated with what the researchers described as an attenuation of age-related metabolic changes. The reported shifts included higher “good” cholesterol and lower “bad” cholesterol in male mice and reduced insulin levels in female mice. (sciencedaily.com)

A key premise of the approach is that cephaloridine can influence the gut microbiome without widespread effects in the rest of the body when administered orally. The researchers and the institutional summary describe cephaloridine as not being absorbed into the bloodstream when taken by mouth, which they argue could limit toxicity and other systemic side effects seen with many drugs. (sciencedaily.com)

In the paper, the authors report that the colanic-acid induction occurred through a mechanism that is independent of cephaloridine’s known antibiotic activity and involves the membrane-bound histidine kinase ZraS, suggesting the drug can act as a chemical signal to shift bacterial metabolism. (dx.doi.org)

The work was supported by the Howard Hughes Medical Institute, and the authors disclose that a patent application has been filed related to the research. (dx.doi.org)

Mitä ihmiset sanovat

Limited initial reactions on X include detailed neutral summaries of the study in a thread by a medical research account, positive commentary from longevity accounts portraying it as a counterintuitive advancement in microbiome-targeted longevity medicine, and one skeptical note on potential antibiotic resistance. Key points highlighted: low-dose cephaloridine boosts colanic acid production by gut bacteria, extending roundworm lifespan and improving mouse metabolic markers like cholesterol and insulin, with gut-confined action minimizing side effects.

Liittyvät artikkelit

Lab illustration of madecassic acid from Centella skincare inhibiting drug-resistant E. coli bacteria.
AI:n luoma kuva

Study finds madecassic acid, a Centella compound used in skincare, can inhibit drug-resistant E. coli in lab tests

Raportoinut AI AI:n luoma kuva Faktatarkistettu

Researchers at the University of Kent, working with University College London, report that madecassic acid—a compound derived from the medicinal herb Centella asiatica and widely used in skincare—can inhibit the growth of antibiotic-resistant E. coli by targeting a bacterial respiratory system not found in humans or other animals.

A probiotic bacterium isolated from kimchi bound strongly to polystyrene nanoplastics in laboratory experiments and was linked to higher nanoplastic excretion in germ-free mice, according to a research summary released by South Korea’s National Research Council of Science & Technology.

Raportoinut AI Faktatarkistettu

Researchers reported at Digestive Disease Week (DDW) 2026 that older mice given fecal microbiota transplants made from their own preserved, younger-age stool samples showed less liver inflammation and injury—and none developed liver cancer in the experiment.

Tämä verkkosivusto käyttää evästeitä

Käytämme evästeitä analyysiä varten parantaaksemme sivustoamme. Lue tietosuojakäytäntömme tietosuojakäytäntö lisätietoja varten.
Hylkää